Literature summary for 3.4.14.5 extracted from

Herman, G.A.; Bergman, A.; Stevens, C.; Kotey, P.; Yi, B.; Zhao, P.; Dietrich, B.; Golor, G.; Schrodter, A.; Keymeulen, B.; Lasseter, K.C.; Kipnes, M.S.; Snyder, K.; Hilliard, D.; Tanen, M.; Cilissen, C.; De Smet, M.; de Lepeleire, I.; Van Dyck, K.; Wang, A.Q.; Zeng, W.; Davies, M.J.; Tanaka, W.; Holst, J.J.
Effect of single oral doses of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on incretin and plasma glucose levels after an oral glucose tolerance test in patients with type 2 diabetes (2006), J. Clin. Endocrinol. Metab., 91, 4612-4619.

Application

Application	Comment	Organism
medicine	in patients with type 2 diabetes, near maximal glucose-lowering efficacy of sitagliptin after single oral doses is associated with inhibition of plasma DPP-4 activity of 80% or greater, corresponding to a plasma sitagliptin concentration of 100 nM or greater, and an augmentation of active glucagon-like peptide-1 and glucose-dependent insulinotropic peptide levels of 2fold or higher after an oral glucose tolerance test	Homo sapiens

Inhibitors	Comment	Organism	Structure
sitagliptin	-	Homo sapiens

Organism	UniProt	Comment	Textmining
Homo sapiens	-	patients with type 2 diabetes	-

Source Tissue	Comment	Organism	Textmining

Synonyms	Comment	Organism
dipeptidyl peptidase-4	-	Homo sapiens

Use of this online version of BRENDA is free under the CC BY 4.0 license. See terms of use for full details.

Release 2023.1 (January 2023)